Varian Medical Systems Inc

Varian Medical Systems — 2018 ASTRO Investor Relations Meeting

67 slides from Varian Medical Systems's conference presentation, Oct 23, 2018

  1. Slide 1: 2018 ASTRO Investor Relations Meeting: Transforming Cancer Care

    Slide 1: 2018 ASTRO Investor Relations Meeting: Transforming Cancer Care

    2018 ASTRO Investor Relations Meeting October 23, 2018 Transforming Cancer Care

  2. Slide 2: Agenda

    Slide 2: Agenda

    FOR INVESTOR USE ONLY Agenda Welcome & Introductions Mike Bruff SVP, Investor Relations, Corporate Planning & Segment Finance Varian Overview & Strategic Framework Dow Wilson President and Chief Executive Officer Innovations in Oncology Kolleen Kennedy Chief Growth Officer and President , Proton Sol

  3. Slide 3: Forward-Looking Statements

    Slide 3: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199

  4. Slide 4: Varian Overview & Strategic Framework

    Slide 4: Varian Overview & Strategic Framework

    FOR INVESTOR USE ONLY Varian Overview & Strategic Framework Dow Wilson President and Chief Executive Officer

  5. Slide 5: Varian today – a snapshot

    Slide 5: Varian today – a snapshot

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Varian today – a snapshot A focused cancer company Global Leader in radiation therapy FY17 revenues $2.6B >8,000 medical linear accelerators >40 worldwide training centers software installs 5,000 proton the

  6. Slide 6: Cancer affects everyone

    Slide 6: Cancer affects everyone

    VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY $2 Trillion Global Economic Burden in 2010 $$$ 24.6 Million New Cancer Cases by 2030 10% Cancer Patients That Have Access To RT in Low Income Countries > 20,000* Linacs needed by 2035; greatest need in low + mid - income

  7. Slide 7: Long-term growth and value creation strategy

    Slide 7: Long-term growth and value creation strategy

    Long - term growth and value creation strategy Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology S

  8. Slide 8: Varian investments in innovation

    Slide 8: Varian investments in innovation

    FOR INVESTOR USE ONLY Varian investments in innovation Achieving a world without fear of cancer Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality prec

  9. Slide 9: Integrated Care

    Slide 9: Integrated Care

    FOR INVESTOR USE ONLY Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality precision treatments with advanced radiation therapy, surgical procedures, int

  10. Slide 10: Integrated Care

    Slide 10: Integrated Care

    FOR INVESTOR USE ONLY Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality precision treatments with advanced radiation therapy, surgical procedures, int

  11. Slide 11: Integrated Care

    Slide 11: Integrated Care

    FOR INVESTOR USE ONLY Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality precision treatments with advanced radiation therapy, surgical procedures, int

  12. Slide 12: Innovation leader in radiation therapy

    Slide 12: Innovation leader in radiation therapy

    Innovation leader in radiation therapy Integrated hardware and software solutions Treatment Delivery & Imaging Hardware makes up ~40% Varian’s business BRACHYTHERAPY HALCYON PROTONS TRUEBEAM FAMILY ADAPTIVE Work in progress; not available for sale Services Services make up ~40% Varian’s business HAR

  13. Slide 13: Leadership by the numbers

    Slide 13: Leadership by the numbers

    Leadership by the numbers First in installed base, customer satisfaction and investment in innovation $1B+ Services business Top rated service provider globally Varian rated #1 IMV Net Promoter Score of 71 1.5M+ SRS and SBRT cases on Varian machines 24 operational proton rooms >8,000 Largest install

  14. Slide 14: Executing on long-term growth strategy

    Slide 14: Executing on long-term growth strategy

    FOR INVESTOR USE ONLY FOR INVESTOR USE ONLY Executing on long - term growth strategy • TrueBeam, ARIA, and Eclipse named 2018 Best in KLAS category leaders • Launched Halcyon 2.0 with kV CBCT imaging • Acquired Mobius Medical Systems and humediQ Key accomplishments – FY 2018 Strengthen Leadership in

  15. Slide 15: Organizing for future growth and success

    Slide 15: Organizing for future growth and success

    FOR INVESTOR USE ONLY Organizing for future growth and success Expanded roles for Varian business leaders • Focus on driving further growth • Expand Proton Solutions offering • FlashForward • Acquisition Integration Office • Strategic Program Management Kolleen Kennedy Chief Growth Officer President

  16. Slide 16: Innovations in Oncology

    Slide 16: Innovations in Oncology

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Innovations in Oncology Kolleen Kennedy Chief Growth Officer and President, Proton Solutions Chris Toth President, Oncology Systems Corey Zankowski SVP, Oncology Software Solutions

  17. Slide 17: ASTRO booth 2018 Featured Products

    Slide 17: ASTRO booth 2018 Featured Products

    ASTRO booth 2018 Featured Products New Portfolio Works - in - Progress ProBeam ® 360 ° Eclipse™ MCO Bravos™ Brachytherapy Halcyon™ KV HyperArc™ ARIA ® Mobile Velocity™ RapidSphere 360 Oncology™ Evinance Vision for Adaptive Therapy Mobius / DoseLab humediQ / Identify Evinance Noona FOR INVESTOR USE O

  18. Slide 18: ASTRO events

    Slide 18: ASTRO events

    ASTRO events • Varian Users Meeting: >1,300 attendees − Community Key Opinion Leader Presentations • Expanding Access to Care through Innovative Clinical School Faculty Program • Comprehensive Research Partner Meetings • Innovations in Proton Therapy Event • SANTRO 10th Anniversary & China Users Eve

  19. Slide 19: Oncology Systems

    Slide 19: Oncology Systems

    Oncology Systems Chris Toth President, Oncology Systems

  20. Slide 20: TrueBeam

    Slide 20: TrueBeam

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY TrueBeam ® >2,000 systems installed Exquisite imaging • Visualization of more targets TrueBeam has treated more SRS/SBRT cases than any other RT platform TrueBeam fueling replacement cycle and take - outs • Versatility driving competitive replacements • Clinac

  21. Slide 21: HyperArc: Removing boundaries in brain radiosurgery

    Slide 21: HyperArc: Removing boundaries in brain radiosurgery

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY John Fiveash , MD Vice Chair, Academic Programs University of Alabama Birmingham NCI Designated Cancer Center FOR INVESTOR USE ONLY 21 HyperArc ™ ( TrueBeam ® platform) Removing boundaries in brain radiosurgery

  22. Slide 22: Halcyon radiotherapy system

    Slide 22: Halcyon radiotherapy system

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Halcyon Countries cleared in >100 Patients treated >5,000 Average uptime 99% Average installation time 7 days “As of 16 th October 2018, we are treating 131 patients in Halcyon Linac installed at Sterling Hospital, Rajkot in just about 15 hours comfortably . T

  23. Slide 23: Halcyon clinical capabilities

    Slide 23: Halcyon clinical capabilities

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Images courtesy of Washington University, St. Louis, School of Medicine Breast – Iterative CBCT Left Breast; Supine Scan Mode: Thorax Fast Scan Time: 17 sec; Breath Hold Dose: 5.9 mGy Prostate – Iterative CBCT Prostate; Supine Scan Mode: Pelvis Large Scan Time

  24. Slide 24: Adaptive solution for every patient

    Slide 24: Adaptive solution for every patient

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY • Artificial Intelligence (AI) driven • Multi - modality imaging at the console − MR, PET, CT • 4D prescriptions • Designed to image and treat fast − Greater patient comfort − Higher image quality • Uncompromised delivery hardware FOR INVESTOR USE ONLY 24 Note

  25. Slide 25: Adaptive use case - Pancreas

    Slide 25: Adaptive use case - Pancreas

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY • AI segmentation of the Pancreas − Using hi - res iCBCT images − In seconds FOR INVESTOR USE ONLY 25 Note: Adaptive is work - in - progress and not available for sale in any market. Adaptive use case - Pancreas

  26. Slide 26: Halcyon: New levels of visualization in CT imaging

    Slide 26: Halcyon: New levels of visualization in CT imaging

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY 26 Hyun Kim, MD Assistant Professor of Radiation Oncology Washington University NCI Designated Cancer Center Halcyon™ New levels of visualization in CT imaging

  27. Slide 27: AI driven multimodality adaptive therapy

    Slide 27: AI driven multimodality adaptive therapy

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY AI driven multimodality adaptive therapy All modalities – every patient – without compromise MR Linac PET Linac CT Linac Varian AI driven multimodality adaptive therapy system Multimodality views exist today from same dataset outside of healthcare, Varian is b

  28. Slide 28: Patient-centered design

    Slide 28: Patient-centered design

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Patient - centered design Enhancing patient experience, while improving care paradigm 70cm bore (Others) 100cm bore (Varian) “ ” There’s no wait time for patients and the machine is very quiet . - Kathleen Luyten , Therapist, Universitaire Ziekenhuizen Leuven

  29. Slide 29: Strengthening the core through acquisitions

    Slide 29: Strengthening the core through acquisitions

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Strengthening the core through acquisitions FOR INVESTOR USE ONLY 29 Quality Assurance: Mobius QA Announced Feb 2018 • DoseLab and Mobius 3D • Total QA Market Opportunity: FY23: $125M Surface Guidance: humediQ IDENTIFY Announced Aug 2018 • IDENTIFY CT, RT, SGR

  30. Slide 30: Brachytherapy: Introducing BRAVOS

    Slide 30: Brachytherapy: Introducing BRAVOS

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Brachytherapy Introducing BRAVOS™ – new HDR afterloader Adding HDR brachy to external beam increases survival by 12 - 13% in Cervical and Prostate cancers New afterloader & applicators fueling market • Streamlined workflow efficiency/patient experience • 3D Pr

  31. Slide 31: Oncology Software Solutions

    Slide 31: Oncology Software Solutions

    Oncology Software Solutions Corey Zankowski SVP, Oncology Software Solutions

  32. Slide 32: Disrupting our market with software, data and technology

    Slide 32: Disrupting our market with software, data and technology

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY VARIAN CONFIDENTIAL – INTERNAL USE ONLY • Migrate to SaaS & cloud solutions • Use informatics to create customer value • Offer services based on automation • Expand into new cancer care modalities Oncology Software Solutions Disrupting our market with software

  33. Slide 33: Unlocking the $3B software opportunity

    Slide 33: Unlocking the $3B software opportunity

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY $250M $400M $550M $150M $550M Oncology Software Solutions Unlocking the $3B opportunity in our nearly 5,000 unique software sites* Eclipse ™ Treatment Planning $950M Velocity ® Image Management ARIA ® Oncology EMR FullScale™ Managed Services HyperArc | $450M R

  34. Slide 34: Unlocking the $3B software opportunity

    Slide 34: Unlocking the $3B software opportunity

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY $250M $400M $550M $150M $550M Oncology Software Solutions Unlocking the $3B opportunity in our nearly 5,000 unique software sites* Eclipse ™ Treatment Planning $950M Velocity ® Image Management ARIA ® Oncology EMR FullScale™ Managed Services HyperArc | $450M R

  35. Slide 35: Noona

    Slide 35: Noona

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Noona Patient reported outcomes (PRO) and symptom management solution Capture high quality oncology PRO data through highly engaged patients Proactively manage patient symptoms to improve outcomes Provide Real World Evidence services for life sciences companie

  36. Slide 36: Patient reported outcomes

    Slide 36: Patient reported outcomes

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Patient reported outcomes Improving survival, lowering costs with smart symptom management Use of ePRO solutions result in: 20% fewer ER visits 30 - 50% fewer clinic calls 10% fewer hospitalizations 20 - 35% improved survival rate Symptom Monitoring With Patie

  37. Slide 37: Integrates the cancer care continuum

    Slide 37: Integrates the cancer care continuum

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Physician Mobile Nurse Navigation Flow sheet Symptom Management Multidisciplinary tumor board Care Team Coordination Practice Management Varian software 2018 Medical Oncology Radiation Oncology RT chart rounds Treatment planning Drug ordering Simulation Treatm

  38. Slide 38: Evidence-based operating system for value-driven cancer care

    Slide 38: Evidence-based operating system for value-driven cancer care

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Physician Mobile Nurse Navigation Flow sheet Symptom Management Multidisciplinary tumor board Care Team Coordination Practice Management Varian software 2023 Medical Oncology Radiation Oncology RT chart rounds Treatment planning as - a - service Drug ordering

  39. Slide 39: Proton Solutions

    Slide 39: Proton Solutions

    Proton Solutions Kolleen Kennedy Chief Growth Officer & President, Proton Solutions

  40. Slide 40: ProBeam proton therapy family

    Slide 40: ProBeam proton therapy family

    VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY ProBeam ® proton therapy family Introducing ProBeam ® 360 ° Proton Therapy System ProBeam ® Single - Room ProBeam ® Multi - Room FOR INVESTOR USE ONLY 40

  41. Slide 41: Introducing ProBeam 360° proton therapy system

    Slide 41: Introducing ProBeam 360° proton therapy system

    VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY 180 m 2 Introducing ProBeam ® 360 ° proton therapy system Future - forward Ultra - high dose rates Exceptional precision 360 ° gantry 25% lower vault cost FOR INVESTOR USE ONLY 41

  42. Slide 42: New Horizons in Cancer Care

    Slide 42: New Horizons in Cancer Care

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY New Horizons in Cancer Care Dee Khuntia, MD Chief Medical Officer

  43. Slide 43: Medical Affairs agenda

    Slide 43: Medical Affairs agenda

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Image here that’s relevant to MA? Agenda 1. SABR - COMET trial Stereotactic Ablative RT for the Comprehensive Treatment of Oligometastatic Tumors 2. Hippocampal avoidance WBRT Phase 3 trial Preservation of Neurocognitive Function with Conform

  44. Slide 44: SBRT improved overall survival in randomized trial

    Slide 44: SBRT improved overall survival in randomized trial

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY SBRT improved overall survival by 50% and doubled progression - free survival in randomized controlled trial Plenary Abstract #5 Stereotactic Ablative RT for the Comprehensive Treatment of Oligometastatic Tumors (SABR - COMET): Results of a r

  45. Slide 45: Hippocampal avoidance WBRT Phase 3 trial

    Slide 45: Hippocampal avoidance WBRT Phase 3 trial

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Conformal avoidance of hippocampus during whole - brain radiotherapy for brain metastases shown to preserve neurocognitive function in Phase 3 trial Brain Mets • ~300K new cases of brain metastases each year in the U.S •

  46. Slide 46: Using advanced IMRT to spare memory

    Slide 46: Using advanced IMRT to spare memory

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Using advanced IMRT to spare memory: the challenge Even low doses to hippocampus damages memory FOR INVESTOR USE ONLY 46 Adapted from Kempermann & Neumann Science 302: 1689 (2003) Avoiding Hippocampus saves memory

  47. Slide 47: Hippocampal-sparing whole-brain radiation therapy

    Slide 47: Hippocampal-sparing whole-brain radiation therapy

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY 47 Hippocampal - sparing whole - brain radiation therapy – Like treating a donut while sparing the center FOR INVESTOR USE ONLY 47

  48. Slide 48: Hippocampal avoidance trial results

    Slide 48: Hippocampal avoidance trial results

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY STUDY DESIGN RESULTS 518 patient randomized trial Whole brain RT (WBRT) vs Hippocampal Avoidance WBRT Median follow - up of 6.1 months Time to neurocognitive failure was longer with Hippocampal Avoidance Neurocognitive failure at 6 months was

  49. Slide 49: RapidPlan model for hippocampal sparing

    Slide 49: RapidPlan model for hippocampal sparing

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Model trained from dozens of expertly planned hippocampal sparing plans Hippocampal - sparing whole brain RT RapidPlan model can be completed in minutes Varian and Northwestern University Anthony Magliari (Varian) Vinai Gondi and Robert Foste

  50. Slide 50: Innovative solutions addressing market demand

    Slide 50: Innovative solutions addressing market demand

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Innovative solutions addressing market demand Clinical realization to market impact FOR INVESTOR USE ONLY 50 $8.7B Installed Base replacement opportunity* TrueBeam ® Halcyon ™ $3B Software Portfolio Opportunity* Eclipse ™ Tx Planning Velocity

  51. Slide 51: FlashForward

    Slide 51: FlashForward

    FlashForward Dee Khuntia, MD Chief Medical Officer

  52. Slide 52: Ultra high dose rates

    Slide 52: Ultra high dose rates

    500 1000 1500 2000 2500 400 cGy 2,400 cGy TrueBeam Clinac TrueBeam Clinac ProBeam Flash ProBeam 2000 4000 6000 8000 10000 Flash 720,000 cGy 0 cGy 100000 200000 300000 400000 720000 500000 Per min 10,000 cGy Ultra high dose rates Flash Range 40 Gy/sec – 120 Gy/sec FOR INVESTOR USE ONLY Source: Varian

  53. Slide 53: Flash spares normal tissue

    Slide 53: Flash spares normal tissue

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Flash spares normal tissue Control 0 Gy/s Standard RT 17 Gy 0.03 Gy/s FLASH 17 Gy 60 Gy/s NORMAL TISSUE SIGNIFICANT FIBROSIS NO APPARENT DAMAGE FOR INVESTOR USE ONLY 53 From Favaudon et al., Sci. Transl. Med., 16 Jul 2014: Vol. 6, Issue 245,

  54. Slide 54: Flash spares normal tissue while maintaining tumor control

    Slide 54: Flash spares normal tissue while maintaining tumor control

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Flash spares normal tissue while maintaining tumor control High dose rate electron RT – published pre - clinical results Flash increases normal tissue sparing compared to conventional dose rate Better tissue sparing with increasing dose rates

  55. Slide 55: Varian pre-clinical proton experiments

    Slide 55: Varian pre-clinical proton experiments

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Varian pre - clinical proton experiments Varian proton experiments FOR INVESTOR USE ONLY 55 Control Conventional protons (1 Gy/sec) Flash protons (40Gy/sec) 3 Groups 392 Mice Age and sex matched 6 Cohorts Sacrificed 1h -

  56. Slide 56: Flash reduced dermatitis and fibrosis

    Slide 56: Flash reduced dermatitis and fibrosis

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Flash resulted in a reduction in radiation induced dermatitis and fibrosis Normal tissue toxicity studies *Average fibrosis scores 25% DERMATITIS 35% reduction in dermatitis* with FLASH vs. Conventional (17.5 Gy) *Average dermatitis scores Co

  57. Slide 57: Normal tissue and tumor control studies underway

    Slide 57: Normal tissue and tumor control studies underway

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Brain Lung Head and Neck Fibrosis induction in tumor microenvironment mimicking normal tissue Neurocognitive evaluation of rats after Flash and conventional radiation Induction of Oral mucositis in mice Normal tissue and tumor control studies

  58. Slide 58: Tumor control preliminary results

    Slide 58: Tumor control preliminary results

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Tumor control preliminary results: Proton FLASH vs Proton Conventional vs No RT 58 Approximate tumor volume (mm^3) Treatment group Control (Untreated) (n=12) 20 40 60 0 Flash (n=24) Conventional (n=24) 50 30 10 70 Tumor

  59. Slide 59: Flash reduces differential gene expression

    Slide 59: Flash reduces differential gene expression

    Normal Lung Tissue Conventional Protons Flash Protons 1,294 639 37 40 Flash reduces differential gene expression normally observed with radiation therapy Different genes are up or down regulated when comparing treatment groups versus the (untreated) control group. FLASH Protons have a gene expressio

  60. Slide 60: Flash offers potential for paradigm shift

    Slide 60: Flash offers potential for paradigm shift

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY VARIAN CONFIDENTIAL – INTERNAL USE ONLY There are very few technologies that come along that offer a potential for paradigm shift – Flash offers that potential. – James M. Metz, MD Professor and Chair Radiation Oncology Executive Director, OncoLink Penn Medici

  61. Slide 61: FlashForward Consortium

    Slide 61: FlashForward Consortium

    FlashForward ™ Consortium Sylvester Comprehensive Cancer Center New York Proton Center Paul Scherrer Institute Holland PTC Particle Therapy Centre University College London Cincinnati Proton Therapy Center University of Maryland Dept of Radiation Oncology Emory Proton Therapy Center Proton Internati

  62. Slide 62: Closing Remarks

    Slide 62: Closing Remarks

    VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY 62 Closing Remarks Dow Wilson President and Chief Executive Officer

  63. Slide 63: In summary, we are…

    Slide 63: In summary, we are…

    FOR INVESTOR USE ONLY In summary, we are… 63 …Driving toward our vision of a world without fear of cancer Delivering on our long - term growth and value creation strategy Growing our net installed base Extending our market - leading, best - in - class product portfolio Becoming a global leader in mu

  64. Slide 64: Q&A

    Slide 64: Q&A

    Q&A

  65. Slide 65: Appendix

    Slide 65: Appendix

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Appendix

  66. Slide 66: SBRT outcomes for prostate cancer

    Slide 66: SBRT outcomes for prostate cancer

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY SBRT delivers impressive cancer control for patients with prostate cancer in largest analysis of long - term SBRT outcomes CONCLUSION “To the best of our knowledge, this is the largest analysis of long - term outcomes following SBRT for PCa,

  67. Slide 67: Innovation leader in radiation therapy

    Slide 67: Innovation leader in radiation therapy

    MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Innovation leader in radiation therapy Integrated hardware and software solutions Treatment Delivery & Imaging Hardware makes up ~40% Varian’s business Digital Health Solutions Software makes up ~20% Varian’s business BRACHYTHERAPY » Integrat

Source: SEC EDGAR · 8-K filed Oct 23, 2018

More decks from Varian Medical Systems Inc